Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease
Authors:
- Gertraud Heinz-PeerGHGertraud Heinz-Peer
- Anita NerudaANAnita Neruda
- Bruno WatschingerBWBruno Watschinger
- Andreas VychytilAVAndreas Vychytil
- Alexandra GeusauAGAlexandra Geusau
- Markus HaumerMHMarkus Haumer
- Michael WeberMWMichael Weber
- 1 October 2010
- journal article
- Published by Elsevier in European Journal of Radiology
- Vol. 76 (1) , 129-134
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium‐Based Contrast Agents?Seminars in Dialysis, 2008
- Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be ConcernedAmerican Journal of Roentgenology, 2007
- Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?British Journal of Radiology, 2007
- Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?Clinical Radiology, 2006
- Nephrogenic Systemic FibrosisJournal of the American Society of Nephrology, 2006
- Nephrogenic systemic fibrosis: An updateCurrent Rheumatology Reports, 2006
- Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrology Dialysis Transplantation, 2006
- Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing DermopathyAmerican Journal of Kidney Diseases, 2005
- Nephrogenic Fibrosing DermopathyThe American Journal of Dermatopathology, 2001
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patientsThe Lancet, 2000